Shamsi T S, Irfan M, Ansari S H, Farzana T, Khalid M Z, Panjwani V K, Baig M I, Shakoor N.
Allogeneic peripheral blood Stem Cell Transplantation in patients with hematological malignancies.
J Coll Physicians Surg Pak Jan ;14(9):522-6.

Objective: To report the initial data on allogeneic peripheral blood stem cell transplantation for haematological malignancies in Pakistan. Design: A single centre descriptive study. Place and Duration of Study: Bismillah Taqee Institute of Health Sciences and Blood Diseases Centre from September 1999 to June 2004. . Patients and Methods: Patients with haematological malignancies were included who had received allogeneic PBSC transplantation of Filgrastim (rhG-CSF) mobilized peripheral blood stem cells from HLA-identical siblings (except one 5/6 antigen sibling) with Busulphan and Cyclophosphamide standard conditioning therapy in all patients. No patient received antibiotics for gut decontamination. Empirical antibiotics included Ceftriaxone and Amikacin for febrile neutropenia, oral Itraconazole for antifungal prophylaxis while oral acyclovir was used for antiviral prophylaxis. All donors and recipients were CMV IgG positive Cyclosporin A / Methotrexate were given for graft versus host disease (GvHD) prophylaxis. Stem cells were harvested using Haemonetics MCS+ cell separator. All patients received G-CSF starting from day +4 until their neutrophil count rose to normal. Results: There were 21 patients with age range of 8-38 years and male to female ratio of 2:1. Engraftment was achieved in all patients; median time to absolute neutrophil count of > 0.5 x 109 /l was 10 days (range 8 – 12 days) and platelet count of > 20 x 109 /l was 14 days (12–17 days). Acute graft versus host disease ( aGvHD) was seen in 7 patients; one patient had grade IV skin and hepatic GvHD; another patient had grade III gut GvHD, grade II GvHD was seen in 3 patients while grade I skin aGvHD was seen in 2 patients. Median hospital stay was 34 days. Treatment related mortality was seen in 3 patients (18%). Chronic GvHD was seen in 5 patients. Four more patients died during the follow-up period. Malaria was seen in 2 while tuberculosis developed in one case. Relapse was seen in 2 patients. The estimated probability of survival at one hundred day, at one year and five years was 82, 47 and 40 percent respectively. Conclusion: Haematopoietic stem cell transplant programme can be developed in a developed country setting. Post transplant complications are similar to what have been reported in the developed countries. In endemic areas malaria could prove to be fatal if not recognised and treated early.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com